PRESDATE

This brand name is authorized in Nigeria.

Active ingredients

The drug PRESDATE contains one active pharmaceutical ingredient (API):

1	Labetalol UNII 1GEV3BAW9J - LABETALOL HYDROCHLORIDE
	Labetalol lowers the blood pressure by blocking peripheral arteriolar alphaadrenoceptors thus reducing peripheral resistance, and by concurrent betablockade, protects the heart from reflex sympathetic drive that would otherwise occur.
	Read more about Labetalol

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-5249	Solution for injection	Presdate Labetalol Hydrochloride Injection USP 50 mg/10 mL INJ_SOL 50 mg/10 mL	Solution for injection Each mL contains: Labetalol Hydrochloride USP 5 mg	28/10/2021
B4-5903	Tablet	Presdate Labetalol Hydrochloride Tablets TAB 200 mg	Each tablet contains: Labetalol Hydrochloride USP 200 mg	28/10/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AG01	Labetalol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AG Alpha and beta blocking agents
Discover more medicines within C07AG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-5249, B4-5903